ZK Angio
Latest Information Update: 23 Jan 2007
At a glance
- Originator Bayer Schering Pharma
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)